<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="Tab1">
 <label>Table 1</label>
 <caption>
  <p>Rheumatic musculoskeletal manifestations associated with SARS-CoV-2 infection</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th align="left"/>
    <th align="left">Reported with SARS-CoV-2</th>
    <th align="left">Clinical characteristics</th>
    <th align="left">Refs.</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td align="left" colspan="4">Musculoskeletal manifestations</td>
   </tr>
   <tr>
    <td align="left"> Arthralgia-Myalgia</td>
    <td align="left">In 14.4–44% of the cases</td>
    <td align="left">
     <p>Early and transient features</p>
     <p>Resolves in 10–15 days</p>
    </td>
    <td align="left">[
     <xref ref-type="bibr" rid="CR21">21</xref>]
    </td>
   </tr>
   <tr>
    <td align="left"> Acute Myositis</td>
    <td align="left">Case report</td>
    <td align="left">
     <p>Symptom of myalgia and proximal muscle weakness preceded respiratory symptom of COVID-19</p>
     <p>Elevate Creatine kinase (CK) level (25,384 IU/L)</p>
     <p>MRI showed muscle edema</p>
     <p>Negative MSA and MAAs</p>
    </td>
    <td align="left">[
     <xref ref-type="bibr" rid="CR22">22</xref>]
    </td>
   </tr>
   <tr>
    <td align="left" colspan="4">Dermatological manifestations</td>
   </tr>
   <tr>
    <td align="left"> COVID toes/pseudo-chilblain</td>
    <td align="left">In ~ 19–59% of the pediatric and young adults</td>
    <td align="left">
     <p>Asymmetrical multiple red–purple pustular or vesicular lesions at distal extremities</p>
     <p>Relatively late feature</p>
    </td>
    <td align="left" rowspan="5">[
     <xref ref-type="bibr" rid="CR23">23</xref>]
    </td>
   </tr>
   <tr>
    <td align="left"> Skin rash</td>
    <td align="left">In ~ 19% of the cases</td>
    <td align="left">
     <p>Transient (6–9 days) urticarial or maculopapular rash</p>
     <p>Associated with severe disease</p>
    </td>
   </tr>
   <tr>
    <td align="left"> Purpura</td>
    <td align="left">Rare</td>
    <td align="left">Punctiform or diffuse</td>
   </tr>
   <tr>
    <td align="left"> Livedoid/necrotic lesions</td>
    <td align="left">In 6% of the elderly with severe disease</td>
    <td align="left">Acral and truncal distribution with ischemic features in severe cases</td>
   </tr>
   <tr>
    <td align="left"> Erythema elevatum diutinum-like rash</td>
    <td align="left">Rare</td>
    <td align="left">Multiple red–purple papulo-nodular lesion over the dorsum of hands</td>
   </tr>
   <tr>
    <td align="left" colspan="4">Neurological manifestations</td>
   </tr>
   <tr>
    <td align="left"> Large vessel stroke in young patients</td>
    <td align="left">Case reports</td>
    <td align="left">
     <p>National Institute of Health Stroke Score range: 13–23</p>
     <p>Probably secondary to endothelitis and coagulopathy secondary to COVID-19</p>
    </td>
    <td align="left">[
     <xref ref-type="bibr" rid="CR24">24</xref>]
    </td>
   </tr>
   <tr>
    <td align="left" colspan="4">Cardiovascular manifestations</td>
   </tr>
   <tr>
    <td align="left"> Myocarditis in absence of previous comorbidities</td>
    <td align="left">Case reports</td>
    <td align="left">
     <p>Likely to occur within 7 days of symptoms</p>
     <p>Circumferential pericardial effusion, global hypokinesia, low ejection fraction and normal cardiac valves on echocardiography</p>
     <p>Normal coronary angiography</p>
     <p>Cardiac MRI: myocardial edema and pattern of late gadolinium-enhancement fulfilling Lake Louis criteria of acute myocarditis</p>
     <p>Improved with supportive care, hydroxychloroquine, lopinavir/ritonavir, and intravenous methylprednisolone</p>
    </td>
    <td align="left">[
     <xref ref-type="bibr" rid="CR25">25</xref>, 
     <xref ref-type="bibr" rid="CR26">26</xref>]
    </td>
   </tr>
   <tr>
    <td align="left" colspan="4">Multisystem autoinflammatory syndrome</td>
   </tr>
   <tr>
    <td align="left"> Cytokine storm/Secondary Hemophagocytic lymphohistiocytosis (sHLH)</td>
    <td align="left">Represents critical patients with SARS-CoV-2 infection</td>
    <td align="left">
     <p>After 8–9 days of the symptom onset</p>
     <p>Unremitting fever, cytopenia, and hyperferritinemia</p>
     <p>Acute respiratory distress syndrome and multiple organ failure</p>
     <p>Interplay of Interferons, interleukins, chemokines, colony-stimulating factors, and TNF-alpha</p>
     <p>Hyperferritinemia and elevated serum IL-6, associated with mortality</p>
     <p>H-score of &gt; 169, 93% sensitivity and 86% specificity for the diagnosis of the sHLH</p>
     <p>Report on improvement with IL-1 and IL-6 inhibitor</p>
    </td>
    <td align="left">[
     <xref ref-type="bibr" rid="CR27">27</xref>]
    </td>
   </tr>
   <tr>
    <td align="left" colspan="4">Post-viral autoimmunity</td>
   </tr>
   <tr>
    <td align="left"> Guillain-Barré syndrome (GBS)</td>
    <td align="left">Case reports</td>
    <td align="left">
     <p>The interval from COVID symptoms to GBS symptoms was 5–10 days</p>
     <p>Axonal or demyelinating variant</p>
     <p>Negative PCR for SARS-CoV-2 from CSF</p>
     <p>One of the patients succumbed to respiratory complications, and the other recovered with IVIg/plasmapheresis</p>
    </td>
    <td align="left">[
     <xref ref-type="bibr" rid="CR5">5</xref>, 
     <xref ref-type="bibr" rid="CR6">6</xref>]
    </td>
   </tr>
   <tr>
    <td align="left"> Kawasaki-like disease</td>
    <td align="left">30-fold increased incidence as compared to the pre-COVID time in Italy</td>
    <td align="left">
     <p>Higher mean age (7.5 years)</p>
     <p>More cardiac involvement, shock syndrome, and macrophage activation syndrome as compared to pre-COVID-19 Kawasaki disease</p>
    </td>
    <td align="left">[
     <xref ref-type="bibr" rid="CR4">4</xref>]
    </td>
   </tr>
   <tr>
    <td align="left" colspan="4">Laboratory findings</td>
   </tr>
   <tr>
    <td align="left"> Positive Antinuclear antibodies (ANA)</td>
    <td align="left">Reported in 35% of the patients</td>
    <td align="left" rowspan="2">
     <p>Single-center report</p>
     <p>No impact on outcome with positive ANA</p>
    </td>
    <td align="left" rowspan="2">[
     <xref ref-type="bibr" rid="CR28">28</xref>]
    </td>
   </tr>
   <tr>
    <td align="left"> Anti-Ro52</td>
    <td align="left">Reported in 4.4% of the patients</td>
   </tr>
   <tr>
    <td align="left"> Antiphospholipid antibodies</td>
    <td align="left">
     <p>Case series (
      <italic>n</italic> = 56)
     </p>
     <p>LAC positive (
      <italic>n</italic> = 25)
     </p>
     <p>Anticardiolipin or anti-β2-glycoprotein I antibodies IgG/IgM (
      <italic>n</italic> = 5)
     </p>
     <p>Case reports (
      <italic>n</italic> = 3)
     </p>
     <p>Anticardiolipin or anti-β2-glycoprotein I antibodies IgA</p>
    </td>
    <td align="left">
     <p>Epiphenomenon rather than autoimmunity</p>
     <p>Expert opinion favoring to start heparin in patients with antiphospholipid test positivity</p>
    </td>
    <td align="left">[
     <xref ref-type="bibr" rid="CR29">29</xref>, 
     <xref ref-type="bibr" rid="CR30">30</xref>]
    </td>
   </tr>
   <tr>
    <td align="left"> Increased 
     <sc>d</sc>-Dimer without DIC
    </td>
    <td align="left">&gt; 0.5 mg/L in 46% of the patients</td>
    <td align="left">
     <p>Higher chance for ICU admission</p>
     <p>&gt; 1 mg/L on admission has 18-times increased mortality (95% CI, 2·6–128·6; 
      <italic>p</italic> = 0·0033)
     </p>
    </td>
    <td align="left">[
     <xref ref-type="bibr" rid="CR31">31</xref>]
    </td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <p>
   <italic>COVID-19</italic> coronavirus disease-2019, 
   <italic>CSF</italic> cerebrospinal fluid, 
   <italic>DIC</italic> disseminated intravascular coagulation, 
   <italic>IL</italic> interleukin, 
   <italic>LAC</italic> lupus anti-coagulant, 
   <italic>MAA</italic> myositis-associated autoantibodies, 
   <italic>MSA </italic>myositis-specific autoantibodies, 
   <italic>RA</italic> rheumatoid arthritis, 
   <italic>PCR</italic> polymerase chain reaction, 
   <italic>SARS-CoV-2</italic> severe acute respiratory syndrome coronavirus-2
  </p>
 </table-wrap-foot>
</table-wrap>
